LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
Morison joins LEO Pharma from Eli Lilly, where she was VP, US Immunology. Prior to that, she held several leadership positions in the US, Australia as well as in the United Kingdom and the Nordics. In addition to her international experience, Morison has a proven track record in building and growing innovative pharmaceutical franchises in different therapeutic areas including orphan diseases.
“Becki Morison’s broad knowledge in immunology, dermatology and specialty pharma will help us to strategically develop our innovative portfolio and execute global launches of best or first-in-class medicines, which is essential to reach our ambition of becoming a global leader in medical dermatology,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Morison succeeds Patrice Baudry, who will take over responsibility for establishing LEO Pharma’s rare disease presence.
“Patrice Baudry’s medical background and his experience in building strong value propositions for our medicines, as he did successfully for our thrombosis business, will be vital in establishing LEO Pharma in rare dermatologic diseases,” Mazzacco continued.
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of re-search and development to advance the science of der-matology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. For more information about LEO Pharma, visit www.leo-pharma.com.